Reductions in SBP were observed with ertugliflozin, a highly selective SGLT2 inhibitor, in the eValuation of ERTugliflozin effIcacy and Safety (VERTIS) phase 3 clinical trials program in patients with T2DM [19–23]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.